MedTrace Logo

New Screening and Diagnostic Cut-off Points of PA Patients

NCT06571084 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 770

Last updated 2024-08-26

No results posted yet for this study

Summary

This study aims to establish the screening and diagnostic cut-off points for primary aldosteronism patients by a novel small molecule "sandwich method" aldosterone and renin chemiluminescent immunoassay.

Conditions

  • Primary Aldosteronism

Sponsors & Collaborators

  • Beijing Anzhen Hospital

    collaborator OTHER

  • First Affiliated Hospital of Chongqing Medical University

    collaborator OTHER

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    collaborator OTHER

  • Wuhan Asia Heart Hospital

    collaborator OTHER

  • China National Center for Cardiovascular Diseases

    lead OTHER_GOV

Principal Investigators

  • Jun Cai · Chinese Academy of Medical Sciences, Fuwai Hospital

  • Zhou Zhou · Chinese Academy of Medical Sciences, Fuwai Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-04
Primary Completion
2024-10-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06571084 on ClinicalTrials.gov